Targeting lentiviral vectors to specific cell types in vivo

被引:119
作者
Yang, Lili
Bailey, Leslie
Baltimore, David [1 ]
Wang, Pin
机构
[1] CALTECH, Div Biol, Pasadena, CA 91125 USA
[2] Univ So Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA
关键词
antibody; gene therapy; lentivirus; retrovirus; targeted gene delivery;
D O I
10.1073/pnas.0604993103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have developed an efficient method to target lentivirus-mediated gene transduction to a desired cell type. It involves incorporation of antibody and fusogenic protein as two distinct molecules into the lentiviral surface. The fusogen is constructed by modifying viral envelope proteins, so that they lack the ability to bind to their cognate receptor but still retain the ability to trigger pH-dependent membrane fusion. Thus, the specificity of such a lentiviral vector is solely determined by the antibody, which is chosen to recognize a specific surface antigen of the desired cell type. This specific binding then induces endocytosis of the surface antigen, bringing the lentivirus into an endosome. There, the fusogen responds to the low pH environment and mediates membrane fusion, allowing the virus core to enter the cytosol. Using CD20 as a target antigen for human B cells, we have demonstrated that this targeting strategy is effective both in vitro and in intact animals. This methodology is flexible and can be extended to other forms of cell type-specific recognition to mediate targeting. The only requirement is that the antibody (or other binding protein) must be endocytosed after interaction with its cell surface-binding determinant.
引用
收藏
页码:11479 / 11484
页数:6
相关论文
共 28 条
[1]   Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types [J].
Boerger, AL ;
Snitkovsky, S ;
Young, JAT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) :9867-9872
[2]  
Coffin J. M., 1997, RETROVIRUSES
[3]   Virus entry: Molecular mechanisms and biomedical applications [J].
Dimitrov, DS .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (02) :109-122
[4]   A hyperfusogenic gibbon ape leukemia envelope glycoprotein: Targeting of a cytotoxic gene by ligand display [J].
Fielding, AK ;
Chapel-Fernandes, S ;
Chadwick, MP ;
Bullough, FJ ;
Cosset, FL ;
Russell, SJ .
HUMAN GENE THERAPY, 2000, 11 (06) :817-826
[5]   Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope [J].
Gollan, TJ ;
Green, MR .
JOURNAL OF VIROLOGY, 2002, 76 (07) :3558-3563
[6]   LIGAND-DIRECTED RETROVIRAL TARGETING OF HUMAN BREAST-CANCER CELLS [J].
HAN, XL ;
KASAHARA, N ;
KAN, YW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) :9747-9751
[7]   Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses [J].
Hatziioannou, T ;
Valsesia-Wittmann, S ;
Russell, SJ ;
Cosset, FL .
JOURNAL OF VIROLOGY, 1998, 72 (06) :5313-5317
[8]   Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies [J].
Jiang, A ;
Chu, THT ;
Nocken, F ;
Cichutek, K ;
Dornburg, R .
JOURNAL OF VIROLOGY, 1998, 72 (12) :10148-10156
[9]   TISSUE-SPECIFIC TARGETING OF RETROVIRAL VECTORS THROUGH LIGAND-RECEPTOR INTERACTIONS [J].
KASAHARA, N ;
DOZY, AM ;
KAN, YW .
SCIENCE, 1994, 266 (5189) :1373-1376
[10]   A stable system for the high-titer production of multiply attenuated lentiviral vectors [J].
Klages, N ;
Zufferey, R ;
Trono, D .
MOLECULAR THERAPY, 2000, 2 (02) :170-176